Provider: - Institution: - Data provided by Europeana Collections- Jena, Univ., Diss., 2004- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 ...Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Although, most of the persistent and life-threatening arrhythmias can be treated with surgical and interventional cardiologic methods, pharmacological intervention is still the most common and ...accessible way of treatment. Recently, antiarrhythmics are very often combined with electrotherapy and ablation in so-called hybrid therapy. Among different antiarrhythmic drugs, potassium channel blockers deserve special attention. All of the compounds able to block repolarizing potassium channels can be divided in to two groups: IIIa which prolong action potential duration (APD) at fast heart rates (amiodarone, dronedarone, dofetilide) and group IIIb that prolonging APD at slow heart rates (bretylium, sotalol). Therefore, in this chapter, the clinical efficacy and the most important clinical trials of above mentioned drugs will be discussed in such arrhythmias as atrial, ventricular tachycardia, atrial flutter, atrial fibrillation and cardiac sudden death.
Provider: - Institution: - Data provided by Europeana Collections- Bochum, Univ., Diss., 2005- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 ...Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- Frankfurt (Main), Univ., Diss., 2005- All metadata published by Europeana are available free of restriction under the Creative ...Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- Göttingen, Georg-August Universität, Diss., 2011- All metadata published by Europeana are available free of restriction under the ...Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: Czech digital library/Česká digitální knihovna - Institution: National Medical Library/Národní lékařská knihovna - Data provided by Europeana Collections- Zdeňka Límanová, Richard Pikner, ...Drahomíra Springer- Lit.: 13- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: - Institution: - Data provided by Europeana Collections- Halle (Saale), Martin-Luther-Universität Halle-Wittenberg, Diss., 2008- All metadata published by Europeana are available free of ...restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Provider: Czech digital library/Česká digitální knihovna - Institution: National Medical Library/Národní lékařská knihovna - Data provided by Europeana Collections- Nejčastějšími a nejzávažnějšími ...vedlejšími účinky široce užívaného antiarytmika amiodaronu jsou tyreopatie. V článku jsou probrány patogenetické mechanismy poškození štítné žlázy, charakteristika látky, frekvence a rozdělení amiodaronových tyreopatií, zvláštnosti v jejich klinickém a laboratorním obraze a zvláštnosti jejich léčby. Je podán přehled doporučených screeningových postupů před zahájením a během léčby amiodaronem. Na závěr jsou zmíněna některá nolá perspektivní antiarytmika s předpokládanou nízkou toxicitou, jejichž výzkum je ve stadiu preklinických a klinických studií, z nichž nejnadějnějším je nejodovaný derivát amiodaronu - dronedaron.- Thyroid disturbances are the most frequent and most important of the side effects of the widespread used antiarrhythmic drug - amiodarone. In this article are discussed characteristics of drug, the pathogenetic mechanisms of thyroid damage, frequency and classification of amiodarone-induced thyroid diseases, distinctions in clinical course, and the specialities in laboratory investigations and treatment. Furthermore, the recommended approaches for the screening before and during administration of amiodarone are given. Finnaly, some perspective new antiarrhythmic drugs with supposed low toxicity as non-iodinated deriváte of amiodarone - dronedarone are mentioned.- Jan Jiskra, Zdenka Límanová- Lit: 23- Souhrn: eng- All metadata published by Europeana are available free of restriction under the Creative Commons CC0 1.0 Universal Public Domain Dedication. However, Europeana requests that you actively acknowledge and give attribution to all metadata sources including Europeana
Supraventrikularna tahikardija je najčešći i klinički najznačajniji oblik fetalne tahiaritmije u trudnoći, a ovisno o trajanju i visini srčane aktivnosti mogu se razviti zatajenje srca i neimuni ...fetalni hidrops, oboje povezani s lošim perinatalnim ishodom. Tijekom drugog i trećeg tromjesečja dijagnoza se često slučajno postavlja ultrazvučnim doplerskim nalazom. Terapijski cilj je konverzija u sinus ritam i oporavak srčane funkcije. Donosimo prikaz slučaja fetalne supraventrikularne tahikardije s neimunim hidropsom, dijagnosticirane u 29. tjednu trudnoće. Terapija digoksinom i amiodaronom bila je uspješna. Ponovo je uspostavljen sinusni ritam srčane frekvencije, a neimuni hidrops se povukao unutar tri tjedna liječenja. Terapija dvama lijekovima sa sinergističkim djelovanjem može biti učinkovitija od monoterapije u blokiranju vjerojatno ponovnog ulaska atrio-ventrikularnog impulsa pomoću sporednog puta u supraventrikularnoj tahikardiji, time dopuštajući povlačenje hidropsa te bolji ishod.
PDF
